



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




AZ 505

Item No. 16875

CAS Registry No.: 1035227-43-0
Formal Name: N-cyclohexyl-3-[[2-(3,4-dichlorophenyl)ethyl]amino]-N-[[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]-propanamide

MF: C₂₉H₃₈Cl₂N₄O₄
FW: 577.6
Purity: ≥98%
UV/Vis.: λ_{max}: 260 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZ 505 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZ 505 in the solvent of choice. AZ 505 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of AZ 505 in these solvents is approximately 30 mg/ml.

AZ 505 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZ 505 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. AZ 505 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

AZ 505 is an inhibitor of the lysine N-methyltransferase SMYD2 (IC₅₀ = 0.12 μM).¹ It is selective for SMYD2 over SMYD3, DOT1L, EZH2, GLP, G9A, and SET7/9 (IC₅₀s = >83.3 μM). AZ 505 (10 mg/kg) delays cyst growth in early- and late-stage *Pdk1* conditional knockout mouse models of polycystic kidney disease.²

References

1. Ferguson, A.D., Larsen, N.A., Howard, T., *et al.* Structural basis of substrate methylation and inhibition of SMYD2. *Structure* **19**(9), 1262-1273 (2011).
2. Li, L.X., Fan, L.X., Zhou, J.X., *et al.* Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. *J. Clin. Invest.* **127**(7), 2751-2764 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM